Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Mallinckrodt
Federal Trade Commission
Healthtrust
Baxter
Queensland Health

Generated: June 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090141

« Back to Dashboard

NDA 090141 describes TADALAFIL, which is a drug marketed by Ajanta Pharma Ltd, Aurobindo Pharma Ltd, Cipla, Dr Reddys Labs Ltd, Hetero Labs Ltd Iii, Lupin Ltd, Mylan Pharms Inc, and Teva Pharms Usa, and is included in eight NDAs. It is available from eleven suppliers. Additional details are available on the TADALAFIL profile page.

The generic ingredient in TADALAFIL is tadalafil. There are twenty-five drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for 090141
Tradename:TADALAFIL
Applicant:Teva Pharms Usa
Ingredient:tadalafil
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 090141
Medical Subject Heading (MeSH) Categories for 090141
Suppliers and Packaging for NDA: 090141
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TADALAFIL tadalafil TABLET;ORAL 090141 ANDA Teva Pharmaceuticals USA, Inc. 0093-3016 0093-3016-65 2 BLISTER PACK in 1 BOX (0093-3016-65) > 15 TABLET, FILM COATED in 1 BLISTER PACK (0093-3016-30)
TADALAFIL tadalafil TABLET;ORAL 090141 ANDA Teva Pharmaceuticals USA, Inc. 0093-3017 0093-3017-56 30 TABLET, FILM COATED in 1 BOTTLE (0093-3017-56)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG
Approval Date:May 22, 2018TE:ABRLD:No
Regulatory Exclusivity Expiration:Mar 26, 2019
Regulatory Exclusivity Use:PATENT CHALLENGE

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:May 22, 2018TE:ABRLD:No
Regulatory Exclusivity Expiration:Mar 26, 2019
Regulatory Exclusivity Use:PATENT CHALLENGE

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:May 22, 2018TE:ABRLD:No
Regulatory Exclusivity Expiration:Mar 26, 2019
Regulatory Exclusivity Use:PATENT CHALLENGE

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Cipla
Deloitte
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.